English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The dairy industry needs evidence-based solutions to mitigate painful procedures and conditions in dairy cattle. The objective of this study was to compare the pharmacokinetic properties of orally versus subcutaneously administered meloxicam in early-lactation dairy cattle. The study was conducted at a commercial dairy herd in southwestern Ontario, Canada. Twelve postpartum cows were enrolled in the study, receiving either subcutaneous meloxicam (MET) at 0.5 mg/kg body weight (n = 6) or oral meloxicam (MOS) at a higher dose of 1.0 mg/kg body weight (n = 6) immediately following parturition. The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), C max (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), T max (5.33 vs. 11.7 h), and AUC 0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively. After controlling for the treatment group, first lactation cows had a significantly higher half-life (4.1 ± 2.1 h), C max (0.56 ± 0.2 µg/mL), and AUC 0→∞ (21.6 ± h * µg/mL) relative to second lactation or greater cows, respectively. Administration of meloxicam through the subcutaneous or oral route results in appreciable, dose-dependent systemic levels.

A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows